Shows high response rates in adults with histiocytic neoplasms, indicating potential effectiveness of trametinib.
Trametinib (MEK inhibitor) shows efficacy in refractory and high-risk adult histiocytic neoplasms. At a median follow-up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
No takes yet. Share an insight, caveat, or question.
Amerikanou et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: